Clinical trials
Recurrent Astrocytoma, IDH-Mutant, Grade 4 clinical trials
Below are recruiting recurrent astrocytoma, idh-mutant, grade 4 clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05789394RecruitingPhase 1
Stem cell treatment for recurrent brain tumor surgery
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
Jacksonville, FloridaAges 18 years+ - NCT06809322RecruitingPhase 3
Vorasidenib maintenance for IDH-mutant astrocytoma after standard treatment
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
InnsbruckAges 18 years+ - NCT06815029RecruitingPhase 1
Modified immune cells for recurrent brain cancer
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+
Hear when a new Recurrent Astrocytoma, IDH-Mutant, Grade 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Recurrent Astrocytoma, IDH-Mutant, Grade 4 trials by city
Studies with a site in or near these metro areas.
Recurrent Astrocytoma, IDH-Mutant, Grade 4 trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for recurrent astrocytoma, idh-mutant, grade 4?
- Yes. Clin2 currently lists 13 recruiting recurrent astrocytoma, idh-mutant, grade 4 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent astrocytoma, idh-mutant, grade 4 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent astrocytoma, idh-mutant, grade 4 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.